Literature DB >> 7034047

Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure.

M Packer, T H Le Jemtel.   

Abstract

This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7034047     DOI: 10.1016/0033-0620(82)90006-8

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  13 in total

1.  Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.

Authors:  A P Good; D V Unverferth; C V Leier
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 2.  Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

Authors:  M Packer
Journal:  Drugs       Date:  1982-07       Impact factor: 9.546

Review 3.  Vasodilators.

Authors:  T T Zsotér
Journal:  Can Med Assoc J       Date:  1983-09-01       Impact factor: 8.262

4.  The role of digitalis in the future.

Authors:  P A Poole-Wilson
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

5.  Acute and chronic effects of captopril therapy in patients with refractory heart failure.

Authors:  W F Walsh; C L Lee
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress.

Authors:  E Kassis; O Amtorp; S Waldorff; P Fritz-Hansen
Journal:  Br Heart J       Date:  1987-11

7.  Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.

Authors:  P Daly; J L Rouleau; D Cousineau; J H Burgess; K Chatterjee
Journal:  Br Heart J       Date:  1986-08

8.  Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study.

Authors:  H Asanoi; S Sasayama; T Sakurai; J D Lee; M Kinoshita; T Ishimura; J Yoshikawa; K Mitsudo; H Sato; S Morioka
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

9.  Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol.

Authors:  J R Dawson; R Canepa-Anson; P Kuan; S R Reuben; P A Poole-Wilson; G C Sutton
Journal:  Br Heart J       Date:  1983-09

10.  Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure.

Authors:  Wilfried Mullens; Zuheir Abrahams; Gary S Francis; George Sokos; Randall C Starling; James B Young; David O Taylor; W H Wilson Tang
Journal:  Am J Cardiol       Date:  2009-02-21       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.